

# Clinical Trial Optimization via Quantum Computing for Drug Development

Kaan Karakas  
Terakki Foundation Schools

**Abstract**—Clinical trials represent one of the most resource-intensive and time-consuming phases of drug development, often constrained by complex patient stratification, high attrition rates, and logistical inefficiencies. Recent advances in quantum computing introduce new computational paradigms capable of addressing combinatorial optimization, probabilistic modeling, and high-dimensional data analysis challenges inherent in clinical research. This paper examines clinical trial optimization via quantum computing, exploring how quantum algorithms and hybrid quantum–classical frameworks can enhance patient recruitment, adaptive trial design, biomarker discovery, and outcome prediction. By synthesizing developments in quantum optimization, machine learning, and biomedical data analytics, the study evaluates the feasibility and potential impact of quantum-enabled methodologies in accelerating drug development pipelines. The findings suggest that quantum computing, when strategically integrated with classical infrastructures, may reduce development timelines, improve decision accuracy, and support more personalized and efficient clinical trial processes.

■ The process of drug development is characterized by extensive experimentation, regulatory scrutiny, and substantial financial investment, with clinical trials representing the most critical and costly stage. Despite advances in biomedical science and digital health technologies, the success rate of drug candidates progressing from early-phase trials to regulatory approval remains limited [1]. Clinical trials are often hindered by challenges such as heterogeneous patient populations, insufficient recruitment, complex inclusion and exclusion criteria, and unpredictable biological variability [8]. These factors contribute to prolonged timelines, escalating costs, and significant uncertainty in therapeutic outcomes.

Traditional computational tools have provided valuable support in trial design, statistical modeling,

and data management; however, they face limitations when confronted with the combinatorial complexity of modern biomedical datasets. The integration of genomic information, electronic health records, wearable device data, and real-time biomarker streams has exponentially increased the dimensionality of clinical decision-making [4]. Classical optimization and machine learning techniques, while powerful, may struggle to efficiently process and extract actionable insights from such vast and intricate data structures within practical time constraints.

Quantum computing has emerged as a promising frontier capable of addressing computational bottlenecks that challenge classical systems [5]. By leveraging quantum mechanical principles such as superposition, entanglement, and quantum interference, quantum algorithms can explore multiple solution states simultaneously and perform certain optimization and sampling tasks more efficiently than their classical counterparts. In the context of clinical

*Digital Object Identifier 10.62802/h19g1j60*

*Date of publication 07 02 2026; date of current version 07 02 2026*

trials, these capabilities present opportunities to refine participant selection, simulate biological interactions at unprecedented scales, and dynamically adjust trial parameters in response to emerging data [11].

One of the most significant potential contributions of quantum computing lies in combinatorial optimization, which is central to clinical trial design [9]. Determining optimal patient cohorts, balancing control and treatment groups, and scheduling multi-site trial logistics involve solving large optimization problems that grow exponentially with added variables [3]. Quantum optimization algorithms and hybrid quantum–classical methods offer alternative pathways for navigating these complex search spaces, potentially reducing computational time and improving solution quality.

Beyond optimization, quantum-enhanced machine learning techniques provide new avenues for predictive analytics and pattern recognition within biomedical datasets. Identifying subtle correlations between genetic markers, treatment responses, and adverse events requires models capable of capturing nonlinear and high-dimensional relationships [10]. Quantum-assisted learning architectures may enable more efficient feature mapping and probabilistic modeling, thereby improving predictive accuracy in outcome forecasting and risk assessment [2]. Such improvements are particularly valuable in adaptive clinical trial frameworks, where real-time decision-making influences both patient safety and research validity.

The application of quantum computing to drug development also aligns with the broader movement toward precision medicine. As therapeutic strategies increasingly emphasize individualized treatment pathways, clinical trials must evolve to accommodate diverse genetic and environmental profiles. Quantum-enabled data processing could support rapid stratification of participants based on multidimensional criteria, enabling more targeted and ethically responsive research methodologies [6]. In this sense, quantum technologies may serve not only as computational accelerators but also as enablers of more patient-centered and equitable trial designs.

Nevertheless, significant challenges accompany the adoption of quantum computing in biomedical

contexts. Current quantum hardware is limited by noise, error rates, and scalability constraints, necessitating hybrid approaches that combine classical reliability with quantum exploratory power [7]. Additionally, ethical considerations related to data privacy, algorithmic transparency, and equitable access to advanced technologies must be carefully addressed. Successful integration, therefore, depends on interdisciplinary collaboration among computer scientists, clinicians, pharmacologists, and policy experts.

This paper explores how quantum computing can be strategically applied to optimize clinical trials and accelerate drug development. It reviews theoretical foundations of quantum algorithms relevant to biomedical optimization, examines emerging hybrid computational models, and discusses practical and ethical considerations for implementation. By positioning quantum computing as a complementary extension to existing computational infrastructures, this study argues that its thoughtful adoption may redefine the efficiency, adaptability, and precision of clinical research in the evolving landscape of pharmaceutical innovation.

## ■ REFERENCES

1. Bakker, J. P., Izmailova, E. S., Clement, A., Hoffmann, S., Leptak, C., Menetski, J. P., & Wagner, J. A. (2025). Regulatory pathways for qualification and acceptance of digital health technology-derived clinical trial endpoints: considerations for sponsors. *Clinical Pharmacology & Therapeutics*, 117(1), 56-72.
2. Banday, M., Zafar, S., Agarwal, P., Alam, M. A., Biswas, S. S., Hussain, I., & Abubeker, K. M. (2025). Predictive analysis of heart disease using quantum-assisted machine learning. *Discover Applied Sciences*, 7(5), 1-16.
3. Becker, J. (2025). Logistics for Cell and Gene Therapies: Challenges and Strategies for Scaling Personalized Medicine. MIT Center for Transportation & Logistics Research Paper, (2025/022).
4. Chen, Y. M., Hsiao, T. H., Lin, C. H., & Fann, Y. C. (2025). Unlocking precision medicine: clinical applications of integrating health records, genetics, and immunology through artificial intelligence. *Journal of Biomedical Science*, 32(1), 16.
5. Columbus Chinnappan, C., Thanaraj Krishnan, P., Elamaran, E., Arul, R., & Sunil Kumar, T. (2025). Quantum computing: Foundations, architecture and

- applications. *Engineering Reports*, 7(8), e70337.
6. Fairburn, S. C., Jehi, L., Bicknell, B. T., Wilkes, B. G., & Panuganti, B. (2025). Applications of quantum computing in clinical care. *Frontiers in medicine*, 12, 1573016.
  7. Keçeci, M. (2025). Accuracy, Noise, and Scalability in Quantum Computation: Strategies for the NISQ Era and Beyond.
  8. Mangalam, M. (2025). AI-driven dynamic grouping for adaptive clinical trials: Rethinking randomization in precision medicine. *Artificial Intelligence in Medicine*, 103272.
  9. Marengo, A., & Santamato, V. (2025). Quantum algorithms and complexity in healthcare applications: a systematic review with machine learning-optimized analysis. *Frontiers in Computer Science*, 7, 1584114.
  10. Pirouzbakht, M., Hamzeh, S., & Soleimani Samarkhazan, H. (2025). Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers. *Clinical and Experimental Medicine*, 25(1), 1-18.
  11. Sun, H. (2025). Advancements in Clinical Trial Methodologies: A Century in Review. *International Journal of Applied Technology in Medical Sciences*, 4(1), 10-17.